Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGEN NASDAQ:ATHA NASDAQ:ORTX OTCMKTS:OSIR NASDAQ:TARS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGENAgenus$4.47+0.4%$5.11$1.38▼$7.34$141.79M1.44381,601 shs187,446 shsATHAAthira Pharma$0.38-0.6%$0.40$0.22▼$0.83$15.15M3.01164,867 shs138,280 shsORTXOrchard Therapeutics$16.70$16.59$4.24▼$16.72$380.09M0.55157,287 shsN/AOSIROsiris Therapeutics$18.99$18.99$7.01▼$19.30$655.69MN/A205,753 shsN/ATARSTarsus Pharmaceuticals$50.60+2.0%$49.04$30.23▼$59.76$2.09B0.81651,695 shs665,576 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGENAgenus+0.45%-11.83%-3.46%0.00%-26.48%ATHAAthira Pharma-0.62%-0.62%-4.74%+23.13%-24.57%ORTXOrchard Therapeutics0.00%0.00%0.00%0.00%0.00%OSIROsiris Therapeutics0.00%0.00%0.00%0.00%0.00%TARSTarsus Pharmaceuticals+2.04%-10.43%-6.66%+23.20%+58.72%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGENAgenus$4.47+0.4%$5.11$1.38▼$7.34$141.79M1.44381,601 shs187,446 shsATHAAthira Pharma$0.38-0.6%$0.40$0.22▼$0.83$15.15M3.01164,867 shs138,280 shsORTXOrchard Therapeutics$16.70$16.59$4.24▼$16.72$380.09M0.55157,287 shsN/AOSIROsiris Therapeutics$18.99$18.99$7.01▼$19.30$655.69MN/A205,753 shsN/ATARSTarsus Pharmaceuticals$50.60+2.0%$49.04$30.23▼$59.76$2.09B0.81651,695 shs665,576 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGENAgenus+0.45%-11.83%-3.46%0.00%-26.48%ATHAAthira Pharma-0.62%-0.62%-4.74%+23.13%-24.57%ORTXOrchard Therapeutics0.00%0.00%0.00%0.00%0.00%OSIROsiris Therapeutics0.00%0.00%0.00%0.00%0.00%TARSTarsus Pharmaceuticals+2.04%-10.43%-6.66%+23.20%+58.72%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGENAgenus 2.50Moderate Buy$14.50224.38% UpsideATHAAthira Pharma 2.00Hold$0.5030.99% UpsideORTXOrchard Therapeutics 0.00N/AN/AN/AOSIROsiris Therapeutics 0.00N/AN/AN/ATARSTarsus Pharmaceuticals 2.71Moderate Buy$66.6731.75% UpsideCurrent Analyst Ratings BreakdownLatest ATHA, TARS, AGEN, OSIR, and ORTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/10/2025AGENAgenusHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$23.009/5/2025TARSTarsus PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/28/2025AGENAgenusHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$23.008/12/2025AGENAgenusZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGENAgenus$103.46M1.38N/AN/A($13.06) per share-0.34ATHAAthira PharmaN/AN/AN/AN/A$1.16 per shareN/AORTXOrchard Therapeutics$22.66M16.77N/AN/A$7.74 per share2.16OSIROsiris TherapeuticsN/AN/AN/AN/AN/AN/ATARSTarsus Pharmaceuticals$182.95M11.67N/AN/A$5.87 per share8.62Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGENAgenus-$227.21M-$7.15N/AN/AN/A-167.52%N/A-81.04%11/11/2025 (Estimated)ATHAAthira Pharma-$96.94M-$1.55N/AN/AN/AN/A-139.40%-106.84%11/6/2025 (Estimated)ORTXOrchard Therapeutics-$150.66M-$0.94N/AN/AN/A-333.90%-74.94%-33.51%N/AOSIROsiris TherapeuticsN/AN/A0.00∞N/AN/AN/AN/AN/ATARSTarsus Pharmaceuticals-$115.55M-$2.33N/AN/AN/A-31.13%-32.36%-21.04%11/12/2025 (Estimated)Latest ATHA, TARS, AGEN, OSIR, and ORTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025AGENAgenus-$0.78-$1.00-$0.22-$1.00$49.71 million$25.70 million8/7/2025Q2 2025ATHAAthira Pharma-$0.18-$0.18N/A-$0.18N/AN/A8/6/2025Q2 2025TARSTarsus Pharmaceuticals-$0.33-$0.48-$0.15-$0.48$95.81 million$102.66 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGENAgenusN/AN/AN/AN/AN/AATHAAthira PharmaN/AN/AN/AN/AN/AORTXOrchard TherapeuticsN/AN/AN/AN/AN/AOSIROsiris TherapeuticsN/AN/AN/AN/AN/ATARSTarsus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGENAgenusN/A0.060.06ATHAAthira PharmaN/A10.8110.81ORTXOrchard Therapeutics0.203.122.98OSIROsiris TherapeuticsN/AN/AN/ATARSTarsus Pharmaceuticals0.225.265.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGENAgenus61.46%ATHAAthira Pharma57.12%ORTXOrchard Therapeutics29.90%OSIROsiris Therapeutics0.28%TARSTarsus Pharmaceuticals90.01%Insider OwnershipCompanyInsider OwnershipAGENAgenus5.50%ATHAAthira Pharma19.80%ORTXOrchard Therapeutics2.91%OSIROsiris Therapeutics43.40%TARSTarsus Pharmaceuticals8.97%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGENAgenus44031.86 million30.11 millionOptionableATHAAthira Pharma4039.44 million31.63 millionOptionableORTXOrchard Therapeutics16622.76 million22.10 millionOptionableOSIROsiris Therapeutics34234.53 millionN/ANot OptionableTARSTarsus Pharmaceuticals5042.21 million38.43 millionOptionableATHA, TARS, AGEN, OSIR, and ORTX HeadlinesRecent News About These CompaniesWoodline Partners LP Trims Stake in Tarsus Pharmaceuticals, Inc. $TARSSeptember 15 at 4:00 AM | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Stock Price Down 4.1% on Insider SellingSeptember 13, 2025 | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Trading Down 4.1% After Insider SellingSeptember 13, 2025 | americanbankingnews.comTarsus Pharmaceuticals (NASDAQ:TARS) Director William Phd Link Sells 27,116 SharesSeptember 12, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Harrow Health (HROW) and IDEAYA Biosciences (IDYA)September 10, 2025 | theglobeandmail.comAdage Capital Partners GP L.L.C. Acquires New Shares in Tarsus Pharmaceuticals, Inc. $TARSSeptember 7, 2025 | marketbeat.comBaird Financial Group Inc. Decreases Stake in Tarsus Pharmaceuticals, Inc. $TARSSeptember 7, 2025 | marketbeat.comCormorant Asset Management LP Sells 100,000 Shares of Tarsus Pharmaceuticals, Inc. $TARSSeptember 6, 2025 | marketbeat.comCutter Capital Management LP Acquires 92,500 Shares of Tarsus Pharmaceuticals, Inc. $TARSSeptember 6, 2025 | marketbeat.comAlly Bridge Group NY LLC Sells 45,212 Shares of Tarsus Pharmaceuticals, Inc. $TARSSeptember 5, 2025 | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Sets New 12-Month High - Time to Buy?September 4, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. $TARS Shares Sold by Frazier Life Sciences Management L.P.September 4, 2025 | marketbeat.comNorthern Trust Corp Grows Stake in Tarsus Pharmaceuticals, Inc. $TARSSeptember 3, 2025 | marketbeat.comGhisallo Capital Management LLC Acquires New Stake in Tarsus Pharmaceuticals, Inc. $TARSSeptember 2, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. $TARS Position Increased by Paradigm Biocapital Advisors LPSeptember 2, 2025 | marketbeat.com5,284 Shares in Tarsus Pharmaceuticals, Inc. $TARS Purchased by FORA Capital LLCSeptember 1, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Recommendation of "Moderate Buy" by AnalystsSeptember 1, 2025 | marketbeat.comDriehaus Capital Management LLC Invests $36.88 Million in Tarsus Pharmaceuticals, Inc. $TARSAugust 31, 2025 | marketbeat.comWellington Management Group LLP Trims Stock Position in Tarsus Pharmaceuticals, Inc. $TARSAugust 31, 2025 | marketbeat.comJump Financial LLC Takes $2.51 Million Position in Tarsus Pharmaceuticals, Inc. $TARSAugust 29, 2025 | marketbeat.comTarsus to Participate in Upcoming Investor ConferencesAugust 27, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025Renaissance Hedge Fund Adds NVIDIA, Follows Buffett Into UNHBy Leo Miller | August 20, 2025With Rate Cuts Ahead, Buffett-Backed Builders Look Like a BuyBy Jordan Chussler | September 4, 2025Constellation Lowers Outlook: Time to Panic on Buffett's Big Bet?By Leo Miller | September 12, 2025ATHA, TARS, AGEN, OSIR, and ORTX Company DescriptionsAgenus NASDAQ:AGEN$4.47 +0.02 (+0.45%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$4.47 +0.00 (+0.11%) As of 09/16/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.Athira Pharma NASDAQ:ATHA$0.38 0.00 (-0.62%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$0.36 -0.02 (-5.95%) As of 09/16/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.Orchard Therapeutics NASDAQ:ORTXOrchard Therapeutics, a Kyowa Kirin company, is a global gene therapy leader focused on ending the devastation caused by genetic and other severe diseases by discovering, developing, and commercializing new treatments that tap into the curative potential of hematopoietic stem cell (HSC) gene therapy. In this approach, a patient’s own blood stem cells are genetically modified outside of the body and then reinserted, with the goal of correcting the underlying cause of disease with a single treatment. Founded in 2015, Orchard’s roots go back to some of the first research and clinical developments involving HSC gene therapy. Our team has played a central role in the evolution of this technology from a promising scientific idea to a potentially life-transforming reality. Today, Orchard is advancing a pipeline of HSC gene therapies designed to address serious diseases where the burden is immense for patients, families and society and current treatment options are limited or do not exist.Osiris Therapeutics OTCMKTS:OSIR$18.99 0.00 (0.00%) As of 04/17/2019Osiris Therapeutics, Inc. researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix and Stravix for treating chronic wounds of diabetic foot ulcers, venous leg ulcers, pressure ulcers, arterial ulcers, and severe burns, as well as surgical and trauma wounds; BIO4 for bone repair and regeneration in spine, trauma, extremity, cranial, and foot and ankle surgeries; and Cartiform for treating articular cartilage lesions in the knee and other joints. The company also develops and markets Menvivo for the repair of meniscus; and TruSkin for treating chronic wounds. It markets and distributes its products directly to physicians, hospitals, and other healthcare providers, as well as through agents and distributors. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.Tarsus Pharmaceuticals NASDAQ:TARS$50.60 +1.01 (+2.04%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$53.00 +2.40 (+4.74%) As of 09/16/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
